High Frequency of Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Sensitive Nucleocapsid Assays

Journal of Infectious Diseases | April 3, 2024

Nkolola JP, Liu J, Collier AY, Jacob-Dolan C, Senussi Y, Borberg E, Swank Z, Walt DR, Barouch DH.

J Infect Dis. 2024

This study was performed using Simoa Homebrew assay(s).

Abstract

Prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is typically measured by nucleocapsid serology assays. In this study, we show that the Simoa serology assay and T-cell intracellular cytokine staining assay are more sensitive than the clinical Elecsys assay for detection of nucleocapsid-specific immune responses. These data suggest that the prevalence of prior SARS-CoV-2 infection in the population may be higher than currently appreciated.

Related Assays

SARS-CoV-2 N PROTEIN ANTIGEN (RUO)

SARS-CoV-2 SPIKE IGG (RUO)

See All Assays